SUL-238

SUL-238 · GEN İlaç ve Sağlık Ürünleri A.Ş.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for SUL-238, covering 2025-12-01 to 2026-03-31. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 2 Study to Assess the Effects of SUL-238 on High Energy Phosphates With ³¹P-MRS in Patients With Early, Untreated Parkinson's Disease [Phase 2]

See pricing